Cargando…

Structural genomics of infectious disease drug targets: the SSGCID

The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium of researchers at Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory that was established to apply structural genomics approaches to drug targets from inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Stacy, Robin, Begley, Darren W., Phan, Isabelle, Staker, Bart L., Van Voorhis, Wesley C., Varani, Gabriele, Buchko, Garry W., Stewart, Lance J., Myler, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169389/
https://www.ncbi.nlm.nih.gov/pubmed/21904037
http://dx.doi.org/10.1107/S1744309111029204
_version_ 1782211472703619072
author Stacy, Robin
Begley, Darren W.
Phan, Isabelle
Staker, Bart L.
Van Voorhis, Wesley C.
Varani, Gabriele
Buchko, Garry W.
Stewart, Lance J.
Myler, Peter J.
author_facet Stacy, Robin
Begley, Darren W.
Phan, Isabelle
Staker, Bart L.
Van Voorhis, Wesley C.
Varani, Gabriele
Buchko, Garry W.
Stewart, Lance J.
Myler, Peter J.
author_sort Stacy, Robin
collection PubMed
description The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium of researchers at Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory that was established to apply structural genomics approaches to drug targets from infectious disease organisms. The SSGCID is currently funded over a five-year period by the National Institute of Allergy and Infectious Diseases (NIAID) to determine the three-dimensional structures of 400 proteins from a variety of Category A, B and C pathogens. Target selection engages the infectious disease research and drug-therapy communities to identify drug targets, essential enzymes, virulence factors and vaccine candidates of biomedical relevance to combat infectious diseases. The protein-expression systems, purified proteins, ligand screens and three-dimensional structures produced by SSGCID con­stitute a valuable resource for drug-discovery research, all of which is made freely available to the greater scientific community. This issue of Acta Crystallographica Section F, entirely devoted to the work of the SSGCID, covers the details of the high-throughput pipeline and presents a series of structures from a broad array of pathogenic organisms. Here, a background is provided on the structural genomics of infectious disease, the essential components of the SSGCID pipeline are discussed and a survey of progress to date is presented.
format Online
Article
Text
id pubmed-3169389
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher International Union of Crystallography
record_format MEDLINE/PubMed
spelling pubmed-31693892011-09-21 Structural genomics of infectious disease drug targets: the SSGCID Stacy, Robin Begley, Darren W. Phan, Isabelle Staker, Bart L. Van Voorhis, Wesley C. Varani, Gabriele Buchko, Garry W. Stewart, Lance J. Myler, Peter J. Acta Crystallogr Sect F Struct Biol Cryst Commun Introduction The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium of researchers at Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory that was established to apply structural genomics approaches to drug targets from infectious disease organisms. The SSGCID is currently funded over a five-year period by the National Institute of Allergy and Infectious Diseases (NIAID) to determine the three-dimensional structures of 400 proteins from a variety of Category A, B and C pathogens. Target selection engages the infectious disease research and drug-therapy communities to identify drug targets, essential enzymes, virulence factors and vaccine candidates of biomedical relevance to combat infectious diseases. The protein-expression systems, purified proteins, ligand screens and three-dimensional structures produced by SSGCID con­stitute a valuable resource for drug-discovery research, all of which is made freely available to the greater scientific community. This issue of Acta Crystallographica Section F, entirely devoted to the work of the SSGCID, covers the details of the high-throughput pipeline and presents a series of structures from a broad array of pathogenic organisms. Here, a background is provided on the structural genomics of infectious disease, the essential components of the SSGCID pipeline are discussed and a survey of progress to date is presented. International Union of Crystallography 2011-08-13 /pmc/articles/PMC3169389/ /pubmed/21904037 http://dx.doi.org/10.1107/S1744309111029204 Text en © Stacy et al. 2011 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
spellingShingle Introduction
Stacy, Robin
Begley, Darren W.
Phan, Isabelle
Staker, Bart L.
Van Voorhis, Wesley C.
Varani, Gabriele
Buchko, Garry W.
Stewart, Lance J.
Myler, Peter J.
Structural genomics of infectious disease drug targets: the SSGCID
title Structural genomics of infectious disease drug targets: the SSGCID
title_full Structural genomics of infectious disease drug targets: the SSGCID
title_fullStr Structural genomics of infectious disease drug targets: the SSGCID
title_full_unstemmed Structural genomics of infectious disease drug targets: the SSGCID
title_short Structural genomics of infectious disease drug targets: the SSGCID
title_sort structural genomics of infectious disease drug targets: the ssgcid
topic Introduction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169389/
https://www.ncbi.nlm.nih.gov/pubmed/21904037
http://dx.doi.org/10.1107/S1744309111029204
work_keys_str_mv AT stacyrobin structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT begleydarrenw structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT phanisabelle structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT stakerbartl structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT vanvoorhiswesleyc structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT varanigabriele structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT buchkogarryw structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT stewartlancej structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid
AT mylerpeterj structuralgenomicsofinfectiousdiseasedrugtargetsthessgcid